GO:0001773 myeloid dendritic cell activation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001773 (myeloid dendritic cell activation) describes the change in morphology and behavior of a dendritic cell after exposure to a cytokine, chemokine, cellular ligand, or soluble factor.
• Myeloid dendritic cell activation is a biological process that bridges innate sensing and adaptive immunity, and it is required for effective T cell priming in tumors and infections [2,5].
• CD40-mediated activation of immune cells, including dendritic cells, can enhance responses to anti-PD-1 therapy in murine intrahepatic cholangiocarcinoma.
• STING-dependent cytosolic DNA sensing in dendritic cells mediates innate immune recognition of immunogenic tumors and is essential for T cell activation.
• IL-6 exocytosis and VAMP3 phosphorylation are mechanistically coupled to dendritic cell activation, linking vesicle trafficking to immune output.
• MyD88 expression in dendritic cells is required for rotavirus-induced B cell activation, showing that myeloid dendritic cell activation shapes humoral immunity.
Description
Myeloid dendritic cell activation (GO:0001773) is the biological process by which a dendritic cell changes its morphology and behavior after exposure to a cytokine, chemokine, cellular ligand, or soluble factor. This process is a central node in innate and adaptive immunity because activated dendritic cells acquire the capacity to process and present antigen, upregulate costimulatory molecules, and migrate to lymphoid organs to prime T cells [2,5]. In the tumor microenvironment, rare activating antigen-presenting cells within the myeloid compartment are critical for T cell immunity, and their activation state determines whether an antitumor response is generated. Similarly, STING-dependent cytosolic DNA sensing in dendritic cells mediates innate immune recognition of immunogenic tumors and is required for downstream T cell activation. Because dendritic cell activation sits at the interface of sensing and effector immunity, it is a high-value target for mechanistic studies and therapeutic manipulation. Researchers studying this process need reliable cell models in which candidate genes can be knocked out, point-mutated, knocked in, or overexpressed to test causality. This article summarizes the authoritative GO definition, the cellular events that constitute myeloid dendritic cell activation, the genes and proteins involved, disease links, and the experimental methods used to study it.
myeloid dendritic cell activation At A Glance
| GO ID | GO:0001773 |
|---|---|
| GO term | myeloid dendritic cell activation |
| Ontology | biological_process |
| Synonym | none |
| Definition | The change in morphology and behavior of a dendritic cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. |
| Major function | Initiation and regulation of innate and adaptive immune responses through dendritic cell maturation and antigen presentation [2,5]. |
| Cellular context | Myeloid dendritic cells, including conventional dendritic cells and related antigen-presenting cells [5,7]. |
| Key upstream triggers | Cytokines, chemokines, cellular ligands, and soluble factors, including CD40 ligation and cytosolic DNA sensing [1,2]. |
| Representative disease link | Cancer immunotherapy response, including anti-PD-1 therapy in intrahepatic cholangiocarcinoma. |
What Is GO:0001773?
According to the Gene Ontology, GO:0001773 (myeloid dendritic cell activation) is defined as the change in morphology and behavior of a dendritic cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor. In practice, this means that a myeloid dendritic cell receives an external signal, transduces it intracellularly, and undergoes measurable phenotypic and functional changes such as altered surface marker expression, cytokine secretion, and enhanced antigen presentation capacity [2,4,5].
Why Is myeloid dendritic cell activation Important in Cell Biology?
Myeloid dendritic cell activation is important because it determines whether the immune system mounts an effective response against tumors, infections, and other threats. Rare activating antigen-presenting cells within the tumor myeloid compartment are critical for T cell immunity, and their activation state can dictate the success of immunotherapy. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma, demonstrating that manipulating dendritic cell activation pathways can improve therapeutic outcomes. STING-dependent cytosolic DNA sensing in dendritic cells mediates innate immune recognition of immunogenic tumors, linking activation of this process to antitumor immunity. In infection settings, dendritic cell expression of MyD88 is required for rotavirus-induced B cell activation, showing that myeloid dendritic cell activation also shapes humoral immunity. Thus, understanding GO:0001773 is essential for immunology, oncology, vaccine design, and infectious disease research.
• Controls T cell priming and antitumor immunity through activation of antigen-presenting dendritic cells [2,5].
• Modulates response to immune checkpoint blockade, including anti-PD-1 therapy.
• Links innate sensing of cytosolic DNA to adaptive immune activation via STING.
• Regulates B cell activation in viral infection through MyD88-dependent dendritic cell signaling.
• Involves vesicle trafficking and cytokine exocytosis, exemplified by VAMP3 phosphorylation and IL-6 release.
• Distinguishes conventional dendritic cell activation from plasmacytoid dendritic cell activation in CD8+ T cell responses.
• Contributes to the recruitment and differentiation of dendritic-like hybrid neutrophils from skull bone marrow in glioblastoma.
• Provides a mechanistic basis for vaccine adjuvant design and immunotherapy combination strategies [1,2].
• Serves as a research target for CRISPR knockout, knock-in, and overexpression studies in immune cell models.
What Happens During myeloid dendritic cell activation?
Signal recognition and receptor engagement
In simple terms: The dendritic cell first detects an external signal, such as a cytokine or a ligand, through receptors on its surface or inside the cell.
Myeloid dendritic cell activation begins when the cell encounters a cytokine, chemokine, cellular ligand, or soluble factor. CD40-mediated immune cell activation is one such trigger that can enhance response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Cytosolic DNA sensing through STING represents another activation route, in which innate immune recognition of immunogenic tumors depends on STING signaling in dendritic cells. These recognition events convert extracellular or intracellular cues into intracellular signals that initiate the activation program.
Intracellular signaling and transcriptional reprogramming
In simple terms: Once the signal is received, signaling pathways inside the cell switch on genes that change the dendritic cell's behavior.
After receptor engagement, intracellular signaling cascades drive transcriptional changes that alter dendritic cell morphology and behavior. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors, indicating that this pathway is a key intracellular route for activation. MyD88-dependent signaling in dendritic cells is required for rotavirus-induced B cell activation, showing that specific adaptor proteins translate activation signals into functional outcomes. These signaling events prepare the dendritic cell for antigen presentation and interaction with T cells.
Vesicle trafficking and cytokine exocytosis
In simple terms: Activated dendritic cells release cytokines by moving vesicles to the cell membrane, a process controlled by proteins like VAMP3.
Phosphorylation of VAMP3 couples IL-6 exocytosis to dendritic cell activation, demonstrating that vesicle trafficking is mechanistically linked to the activation process. This step allows the dendritic cell to secrete cytokines such as IL-6, which can influence neighboring immune cells. The coupling of exocytosis to activation highlights that morphological and behavioral changes in dendritic cells include regulated secretion.
Antigen presentation and T cell priming
In simple terms: The activated dendritic cell displays antigens to T cells and provides signals that turn T cells on.
A central outcome of myeloid dendritic cell activation is the ability to present antigen and prime T cells. Rare activating antigen-presenting cells within the tumor myeloid compartment are critical for T cell immunity, and their activation state determines the strength of the T cell response. Distinctive CD8+ T cell activation by antigen-presenting plasmacytoid dendritic cells compared to conventional dendritic cells further illustrates that different dendritic cell subsets can shape T cell responses in specific ways. This step connects innate activation to adaptive immunity.
Interaction with the tissue microenvironment
In simple terms: Activated dendritic cells also communicate with other cells in their surroundings, including in tumors and bone marrow niches.
Myeloid dendritic cell activation does not occur in isolation; it is influenced by the tissue microenvironment. Glioblastoma induces the recruitment and differentiation of dendritic-like hybrid neutrophils from skull bone marrow, showing that tumors can reprogram myeloid cells toward dendritic-like states. In tumors, the myeloid compartment contains rare activating antigen-presenting cells that are critical for T cell immunity. These interactions demonstrate that activation is shaped by both local and systemic signals.
Key Genes Involved in GO:0001773 myeloid dendritic cell activation
The following genes and proteins are experimentally implicated in myeloid dendritic cell activation or in closely related antigen-presenting cell functions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD40 | Costimulatory receptor that mediates immune cell activation | CD40-mediated activation enhances anti-PD-1 response in murine intrahepatic cholangiocarcinoma |
| STING1 | Cytosolic DNA sensor adaptor in innate immune signaling | STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors |
| MYD88 | Adaptor protein in Toll-like receptor and IL-1 receptor signaling | Dendritic cell expression of MyD88 is required for rotavirus-induced B cell activation |
| VAMP3 | Vesicle-associated membrane protein involved in exocytosis | Phosphorylation of VAMP3 couples IL-6 exocytosis to dendritic cell activation |
| IL6 | Cytokine released during dendritic cell activation | IL-6 exocytosis is coupled to dendritic cell activation via VAMP3 |
| ITGAX | Integrin alpha X, a marker of myeloid dendritic cells | Used to identify myeloid antigen-presenting cells in tumor studies |
| ITGAE | Integrin alpha E, associated with dendritic cell subsets | Helps define activating antigen-presenting cells in the tumor myeloid compartment |
| XCR1 | Chemokine receptor marking conventional dendritic cell subset 1 | Used to identify rare activating antigen-presenting cells critical for T cell immunity |
| CLEC9A | C-type lectin receptor for dead cell antigen uptake | Marks a dendritic cell subset involved in antigen presentation |
| BATF3 | Transcription factor required for conventional dendritic cell subset 1 development | Defines dendritic cell subsets relevant to T cell priming |
| IRF8 | Transcription factor regulating dendritic cell development and function | Associated with conventional dendritic cell identity and activation |
| ZBTB46 | Transcription factor marking conventional dendritic cells | Used to distinguish conventional dendritic cells from other myeloid cells |
| CCR7 | Chemokine receptor mediating dendritic cell migration to lymph nodes | Supports the migration step of dendritic cell activation |
| CD80 | Costimulatory ligand for T cell activation | Upregulated on activated dendritic cells to prime T cells |
| CD86 | Costimulatory ligand for T cell activation | Upregulated on activated dendritic cells to prime T cells |
| H2-AB1 | MHC class II molecule for antigen presentation | Required for presentation of antigen to CD4+ T cells |
| TAP1 | Transporter associated with antigen processing | Supports MHC class I antigen presentation in activated dendritic cells |
How Is myeloid dendritic cell activation Regulated?
Myeloid dendritic cell activation is regulated at multiple levels, including receptor-proximal signaling, adaptor protein function, and vesicle trafficking. MyD88 expression in dendritic cells is required for rotavirus-induced B cell activation, indicating that this adaptor is a non-redundant regulator of activation-dependent humoral immunity. STING-dependent cytosolic DNA sensing provides an upstream regulatory input that mediates innate immune recognition of immunogenic tumors. CD40-mediated immune cell activation can enhance response to anti-PD-1, showing that costimulatory pathways regulate the strength and therapeutic impact of dendritic cell activation. Phosphorylation of VAMP3 couples IL-6 exocytosis to dendritic cell activation, adding a post-translational regulatory layer that controls cytokine release. Together, these mechanisms tune the magnitude and quality of myeloid dendritic cell activation.
myeloid dendritic cell activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD40 | Intrahepatic cholangiocarcinoma and anti-PD-1 response | Murine intrahepatic cholangiocarcinoma model with CD40 activation |
| STING1 | Immunogenic tumors and innate immune recognition | STING-dependent tumor models and dendritic cell knockout |
| MYD88 | Rotavirus infection and B cell activation | Dendritic cell-specific MyD88 knockout in rotavirus infection |
| VAMP3 | Dendritic cell activation and IL-6 exocytosis | Phosphorylation-site mutant and knockout dendritic cell models |
| ITGAX/ITGAE/XCR1 | Tumor myeloid compartment and T cell immunity | Tumor models with rare activating antigen-presenting cell analysis |
Cancer immunotherapy and anti-PD-1 response
Myeloid dendritic cell activation is directly linked to cancer immunotherapy outcomes. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma, demonstrating that activating this pathway can overcome resistance to checkpoint blockade. STING-dependent cytosolic DNA sensing in dendritic cells mediates innate immune recognition of immunogenic tumors, providing a mechanistic basis for therapies that aim to trigger this process. Rare activating antigen-presenting cells within the tumor myeloid compartment are critical for T cell immunity, and their presence or absence can determine whether an antitumor response occurs.
Glioblastoma and myeloid cell reprogramming
Glioblastoma induces the recruitment and differentiation of dendritic-like hybrid neutrophils from skull bone marrow, showing that brain tumors can reprogram myeloid cells toward dendritic-like states. This finding links myeloid dendritic cell activation biology to the tumor microenvironment and suggests that local bone marrow niches contribute to immune cell phenotypes in glioblastoma.
Viral infection and humoral immunity
Dendritic cell expression of MyD88 is required for rotavirus-induced B cell activation, indicating that myeloid dendritic cell activation is necessary for certain antiviral B cell responses. This connects GO:0001773 to infectious disease and vaccine immunology, where dendritic cell activation is a prerequisite for robust antibody responses.
Dendritic cell subset differences in T cell activation
Distinctive CD8+ T cell activation by antigen-presenting plasmacytoid dendritic cells compared to conventional dendritic cells highlights that different dendritic cell subsets can activate T cells in different ways. Plasmacytoid dendritic cells have been described as a dendritic cell in disguise, further emphasizing the heterogeneity relevant to activation studies.
From myeloid dendritic cell activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is CD40 required for enhanced anti-PD-1 response? | CD40 knockout or activation models in murine intrahepatic cholangiocarcinoma |
| Does STING in dendritic cells mediate tumor recognition? | STING1 knockout dendritic cells in immunogenic tumor models |
| Is MyD88 in dendritic cells required for B cell activation? | Dendritic cell-specific MYD88 knockout in rotavirus infection |
| Does VAMP3 phosphorylation control IL-6 exocytosis? | VAMP3 point-mutation or knockout dendritic cell models |
| Which myeloid cells are critical for T cell immunity? | Tumor myeloid compartment profiling with antigen-presenting cell markers |
| How do dendritic cell subsets differ in T cell activation? | Conventional versus plasmacytoid dendritic cell co-culture systems [7,8] |
How to Study the myeloid dendritic cell activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface marker expression and cell frequency | Identifying activated myeloid dendritic cells and subsets |
| Cytokine ELISA | Secretion of cytokines such as IL-6 | Assessing dendritic cell activation and exocytosis |
| Genetic knockout | Requirement of a gene for activation | Testing MyD88 or STING dependence [2,6] |
| Phospho-protein analysis | Post-translational modification status | Measuring VAMP3 phosphorylation during activation |
| T cell co-culture | T cell priming and activation | Comparing dendritic cell subsets for CD8+ T cell activation |
| Tumor model profiling | Myeloid compartment composition | Dissecting rare activating antigen-presenting cells |
| B cell activation assay | Humoral immune response readout | Testing dendritic cell MyD88 requirement in rotavirus infection |
| CD40 activation assay | Costimulatory pathway engagement | Evaluating anti-PD-1 combination strategies |
Flow cytometry and surface marker analysis
Flow cytometry is widely used to identify and quantify activated myeloid dendritic cells based on surface markers. Rare activating antigen-presenting cells within the tumor myeloid compartment have been dissected using marker-based approaches, revealing their critical role in T cell immunity. Markers such as ITGAX, XCR1, CLEC9A, and ZBTB46 help distinguish dendritic cell subsets and activation states.
Cytokine and exocytosis assays
Measuring cytokine release is a direct way to assess dendritic cell activation. Phosphorylation of VAMP3 couples IL-6 exocytosis to dendritic cell activation, so IL-6 secretion assays can report on this process. Such assays can be combined with vesicle trafficking inhibitors or genetic perturbations to test mechanism.
Genetic perturbation and signaling analysis
Knockout and knockdown approaches are used to test the requirement for specific genes in myeloid dendritic cell activation. Dendritic cell expression of MyD88 is required for rotavirus-induced B cell activation, a conclusion supported by genetic loss-of-function studies. STING-dependent cytosolic DNA sensing has been dissected using genetic models to show its role in innate immune recognition of immunogenic tumors.
T cell co-culture and functional readouts
Co-culture of activated dendritic cells with T cells allows researchers to measure T cell priming and activation. Distinctive CD8+ T cell activation by antigen-presenting plasmacytoid dendritic cells compared to conventional dendritic cells has been demonstrated using such functional assays. These readouts connect molecular changes in dendritic cells to adaptive immune outcomes.
How CRISPR Can Be Used to Study GO:0001773 myeloid dendritic cell activation
Knockout
CRISPR knockout is used to delete candidate genes in dendritic cell models to test whether they are required for myeloid dendritic cell activation. For example, loss-of-function studies support the conclusion that dendritic cell expression of MyD88 is required for rotavirus-induced B cell activation. Knockout of STING1 can be used to test the role of cytosolic DNA sensing in innate immune recognition of immunogenic tumors.
Point Mutation
CRISPR point mutation allows researchers to introduce specific amino acid changes to test post-translational regulatory mechanisms. Phosphorylation of VAMP3 couples IL-6 exocytosis to dendritic cell activation, so mutating the relevant phosphorylation site can directly test its function. This approach is valuable when a gene is essential and complete knockout would be lethal or confound interpretation.
Knock-in
CRISPR knock-in can be used to add tags, reporters, or humanized sequences to genes involved in dendritic cell activation. Tagged knock-in of markers such as XCR1 or CLEC9A can facilitate tracking of specific dendritic cell subsets in tumor models. Knock-in of reporter cassettes downstream of activation-responsive promoters can provide a live readout of GO:0001773.
Overexpression
CRISPR overexpression or cDNA-based overexpression can test whether increasing the activity of a pathway is sufficient to drive dendritic cell activation. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma, suggesting that boosting costimulatory signaling can be beneficial. Overexpression models can complement knockout studies to establish sufficiency versus necessity.
How EDITGENE Supports myeloid dendritic cell activation Research
Researchers studying myeloid dendritic cell activation-related genes often need to determine whether a candidate gene is causally involved in the process, and CRISPR-based cell models provide a rigorous way to test necessity and sufficiency. EDITGENE offers a suite of services designed to support these experiments, from knockout and point-mutation cell lines to knock-in reporters, overexpression models, and CRISPR library screening with bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for myeloid dendritic cell activation research.
Frequently Asked Questions About myeloid dendritic cell activation
What is myeloid dendritic cell activation (GO:0001773)?
Myeloid dendritic cell activation is the change in morphology and behavior of a dendritic cell resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, as defined by the Gene Ontology [2,4,5].
What genes are involved in myeloid dendritic cell activation?
Genes and proteins experimentally implicated include CD40, STING1, MYD88, VAMP3, and IL6, as well as dendritic cell subset markers such as XCR1, CLEC9A, and ZBTB46 [1,2,4,5,6].
Why is myeloid dendritic cell activation important for cancer immunotherapy?
It is important because rare activating antigen-presenting cells are critical for T cell immunity, and CD40-mediated activation can enhance anti-PD-1 responses in murine intrahepatic cholangiocarcinoma [1,5].
How does STING signaling relate to myeloid dendritic cell activation?
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors, linking this pathway to dendritic cell activation and antitumor immunity.
What role does MyD88 play in dendritic cell activation?
Dendritic cell expression of MyD88 is required for rotavirus-induced B cell activation, showing that MyD88 is a key adaptor in activation-dependent humoral immunity.
How is IL-6 release connected to dendritic cell activation?
Phosphorylation of VAMP3 couples IL-6 exocytosis to dendritic cell activation, linking vesicle trafficking to cytokine release.
Do plasmacytoid and conventional dendritic cells activate T cells differently?
Yes, distinctive CD8+ T cell activation by antigen-presenting plasmacytoid dendritic cells compared to conventional dendritic cells has been reported, and plasmacytoid dendritic cells have been described as a dendritic cell in disguise.
Can tumors reprogram myeloid cells toward dendritic-like states?
Glioblastoma induces the recruitment and differentiation of dendritic-like hybrid neutrophils from skull bone marrow, indicating that tumors can influence myeloid cell phenotypes.
What methods are used to study myeloid dendritic cell activation?
Common methods include flow cytometry, cytokine assays, genetic perturbation, and T cell co-culture, as used in studies of dendritic cell subsets and activation [4,5,6,7].
How can CRISPR help study myeloid dendritic cell activation?
CRISPR knockout, point mutation, knock-in, and overexpression can test necessity and sufficiency of candidate genes, complementing studies such as those on MyD88 and STING [2,6].
Conclusion
GO:0001773 (myeloid dendritic cell activation) is a central biological process that converts innate sensing into adaptive immunity. It is triggered by cytokines, chemokines, cellular ligands, and soluble factors, and it involves signaling, transcriptional reprogramming, vesicle trafficking, and antigen presentation [2,4,5]. Experimental evidence links this process to cancer immunotherapy, viral infection, and tumor microenvironment reprogramming [1,2,3,6]. Studying the genes that regulate myeloid dendritic cell activation with CRISPR-based models can reveal causal mechanisms and identify therapeutic targets.
References
- 1. Diggs LP et al.. 2021. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.. J Hepatol 74(5):1145-1154 PMID: 33276030
- 2. Woo SR et al.. 2014. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.. Immunity 41(5):830-42 PMID: 25517615
- 3. Lad M et al.. 2024. Glioblastoma induces the recruitment and differentiation of dendritic-like "hybrid" neutrophils from skull bone marrow.. Cancer Cell 42(9):1549-1569.e16 PMID: 39255776
- 4. Chen T et al.. 2025. Phosphorylation of VAMP3 couples IL-6 exocytosis to dendritic cell activation.. J Cell Sci 138(19) PMID: 40977280
- 5. Broz ML et al.. 2014. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.. Cancer Cell 26(5):638-52 PMID: 25446897
- 6. Blutt SE et al.. 2025. Dendritic cell expression of MyD88 is required for rotavirus-induced B cell activation.. J Virol 99(5):e0065325 PMID: 40304491
- 7. van der Sluis RM et al.. 2025. Distinctive CD8(+) T cell activation by antigen-presenting plasmacytoid dendritic cells compared to conventional dendritic cells.. Cell Rep 44(3):115413 PMID: 40073016
- 8. Arroyo Hornero R et al.. 2023. Plasmacytoid dendritic cells: A dendritic cell in disguise.. Mol Immunol 159:38-45 PMID: 37269733
